According to new data from the National Health and Nutrition Examination Survey (NHANES), the obesity rate in the United States dropped by roughly two percentage points between 2020 and 2023.

There is no direct evidence that links the declining rates with the growing popularity of GLP-1 prescription weight loss drugs such as Wegovy, Ozempic and Mounjaro. However, the Financial Times said it is “highly likely” drugs played a major role.

According to the Mayo Clinic, one in eight Americans has used prescription weight loss drugs, which can result in a total body weight loss of 3-12 percent more than lifestyle changes alone. College graduates, who are more growing more interested in weight loss drugs, are seeing the steepest decline in obesity rates. The usage of these medications took off in 2021, right in the period when the drop was confirmed, as reported by The Independent.

Jim Roza, chief scientific officer at Layn Natural Ingredients (China/Irvine, CA), said GLP-1 agonists are being promoted as a solution to obesity, but due to high costs, side effects, availability concerns and long-term commitment, they are not the only solution in addressing the obesity epidemic.

“Studies have shown that eating foods high in protein, healthy fats, and fiber can stimulate the release of this hormone thereby slowing digestion and promoting satiety both of which are key factors in weight management,” Roza said. “Consumers should also be cautious of claims made for the polyphenol, berberine, as a natural alternative to these drugs. While some research has shown that berberine may be helpful in promoting healthy blood sugar and supporting a healthy inflammatory response, there is not enough evidence to declare it as being bioequivalent.”